WebMay 15, 2013 · Novartis v. Union of India case law interpretation on Obviousness Novartis filed an application for grant of patent for chemical compound called Imatinib Mesylate which is a therapeutic drug for chronic myeloid leukemia and certain kinds of tumours and is marketed under the names “Glivec” or “Gleevec” at the Chennai Patent Office on July 17, … Novartis v. Union of India & Others is a landmark decision by a two-judge bench of the Indian Supreme Court on the issue of whether Novartis could patent Gleevec in India, and was the culmination of a seven-year-long litigation fought by Novartis. The Supreme Court upheld the Indian patent office's rejection of the … See more History of Patent laws and pharma industry in India As part of the Commonwealth, India inherited its intellectual property laws from Great Britain. However, after gaining independence in … See more Novartis The legal team of Novartis was led by ex-Solicitor General of India Gopal Subramaniam and senior advocate T. R. Andhyarujina. … See more The decision received extensive coverage from Indian and international media. It reignited debates on balancing public good with monopolistic pricing and innovation with affordability. Several commenters, including Novartis, noted that a … See more Supreme Court decided the matter de novo looking into matters of both fact and law. The court first analysed the question of prior art by looking into Zimmerman patent and the related … See more

Case analysis – Novartis Ag v. Union of India - iPleaders

WebApr 11, 2024 · Sign up. See new Tweets WebSupreme Court of India. Novartis Ag vs Union Of India & Ors on 1 April, 2013. Author: ..…..………………………..J. Bench: Aftab Alam, Ranjana Prakash Desai. REPORTABLE IN THE SUPREME COURT OF INDIA CIVIL APPELLATE JURISDICTION CIVIL APPEAL Nos. 2706-2716 OF 2013 (ARISING OUT OF SLP(C) Nos. 20539-20549 OF 2009)NOVARTIS AG … smith watson topper

MillenniumPost on Twitter

WebFeb 5, 2016 · The judgment rendered by the Supreme Court in the case of Novartis AG (“Novartis”) v. Union of India is one of the landmark judgements of the Supreme Court. The decision came as a relief for millions of people around the world to have access to medicines at a low cost, thus preventing the pharmaceutical industries from “evergreening … WebSep 19, 2013 · The Indian Supreme Court’s decision in Novartis v Union of India (UOI), decided earlier this year, formalizes a concerted and focused attempt by Indian law-makers to reject trivial secondary pharmaceutical inventions. Webcompanies vs. MNC pharmaceutical companies pre 1970 and post 1970) (iii) why pharmaceutical, chemical and food product patents were not permitted till 2005, (iv) how India had to retrospectively introduce product patent regime after having lost at the WTO (World Trade Organization), wherein the WTO panel and the appellate body had smith watson funeral home